NEW YORK, Oct. 23, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc.(NASDAQ: SIGA) ("SIGA" or the "Company")

SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company had been conducting a clinical trial to evaluate the efficacy and safety of TPOXX (aka tecovirimat) in the treatment of mpox in combination with standard of care. On August 15, 2024, the preliminary analysis of the PALM 007 clinical trial revealed that TPOXX had failed to achieve its primary endpoint.

NEW YORK, Sept. 30, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc.(NASDAQ: SIGA) ("SIGA" or the "Company")

SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company had been conducting a clinical trial to evaluate the efficacy and safety of TPOXX (aka tecovirimat) in the treatment of mpox in combination with standard of care. On August 15, 2024, the preliminary analysis of the PALM 007 clinical trial revealed that TPOXX had failed to achieve its primary endpoint.

NEW YORK, Sept. 26, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating potential securities claims on behalf of purchasers of SIGA Technologies, Inc.(NASDAQ: SIGA) ("SIGA" or the "Company")

SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus. The Company had been conducting a clinical trial to evaluate the efficacy and safety of TPOXX (aka tecovirimat) in the treatment of mpox in combination with standard of care. On August 15, 2024, the preliminary analysis of the PALM 007 clinical trial revealed that TPOXX had failed to achieve its primary endpoint.